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Outcomes after umbilical cord blood transplantation (UCBT) for chronic lymphocytic leukemia (CLL)/small
lymphocytic lymphoma (SLL) are unknown. We analyzed outcomes of 68 patients with poor-risk CLL/SLL
who underwent reduced-intensity (RIC) UCBT from 2004 to 2012. The median age was 57 years and
median follow-up 36 months; 17 patients had del 17p/p53mutation, 19 patients had ﬂudarabine-refractory
disease, 11 relapsed after autologous stem cell transplantation, 8 had diagnosis of prolymphocytic leu-
kemia, 4 had Richter syndrome, and 8 underwent transplantation with progressive or refractory disease.
The most common RIC used was cyclophosphamide, ﬂudarabine, and total body irradiation (TBI) in 82%;
15 patients received antithymocyte globulin. Most of the cord blood grafts were HLA mismatched and 76%
received a double UCBT. Median total nucleated cells collected was 4.7  107/kg. The cumulative in-
cidences (CI) of neutrophil and platelet engraftment were 84% and 72% at 60 and 180 days respectively;
day 100 graft-versus-host disease (GVHD) (grade II to IV) was 43% and 3-year chronic GVHD was 32%. The
CI of relapse, nonrelapse mortality, overall survival, and progression-free survival (PFS) at 3 years weredgments on page 1521.
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E. Xavier et al. / Biol Blood Marrow Transplant 21 (2015) 1515e1523151616%, 39%, 54%, and 45%, respectively. Fludarabine-sensitive disease at transplantation and use of low-dose
TBI regimens were associated with acceptable PFS. In conclusion, use of RIC-UCBT seems to be feasible in
patients with poor-risk CLL/SLL and improved outcomes were observed in patients with ﬂudarabine-
sensitive disease who received low-dose TBI regimens.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION progression, as deﬁned by the centers; and nonrelapse mortality (NRM),
Chronic lymphocytic leukemia (CLL) is a heterogeneous
disease with a variable clinical course and survival can range
from months to decades, according to different biological
features [1,2]. Poor-risk disease is characterized bymutations
or deletions of the TP53 gene [3-7], nonresponse or early
relapse after purine analogue treatment (within 12 months),
or relapse (less than 24 months) after purine analogue
combination therapy [8].
Until now, allogeneic stem cell transplantation (allo-
HSCT) has been accepted as standard of care in ﬁt patients
with poor-risk CLL [8-10]. Two drugs inhibiting downstream
signaling of the B cell receptor, ibrutinib and idelalisib, have
recently been approved. These drugs expose a very favorable
risk beneﬁt proﬁle for patients with refractory CLL/small
lymphocytic lymphoma (SLL) [11]. Longer follow-up is
needed to better assess the safety and efﬁcacy of these drugs
but clearly they do not have the potential to eradicate the
disease. Comparative studies with allo-HSCT are lacking and
this therapeutic tool is still the only therapy to evoke the
graft-versus-leukemia (GVL) effect that is highly active in
achieving and maintaining disease control, even in advanced
stages of CLL/SLL [12,13]. Although the role of allo-HSCT in
the therapeutic algorithm may have to be redeﬁned, allo-
HSCT will maintain its place in the treatment of patients
with refractory stages of CLL/SLL.
In recent years, the use of reduced-intensity conditioning
(RIC) regimens in the allo-HSCT setting has become standard
treatment, even in poor-risk CLL, and it may lead to cure
[14,15]. Almost exclusively, outcomes on matched related or
unrelated donor transplantation have been published and
data on alternative stem cell donors are lacking. Generally,
clinical experiencewith umbilical cord blood transplantation
(UCBT) in poor-risk malignancies has increased in recent
years, especially with the use of double UCBT, which allows
adult patients to proceed to allo-HSCT [16]. Nevertheless, to
our knowledge, no studies have yet addressed directly the
role of UCBT speciﬁcally for CLL/SLL. Therefore, we analyzed
results of unrelated UCBT in CLL/SLL patients and identiﬁed
risk factors associated with outcomes.METHODS
Study Design: Patients and Deﬁnitions
The primary objective of this study was to describe progression-free
survival (PFS) after UCBT and to identify risk factors in a retrospective reg-
istry analysis. We analyzed adult patients with CLL/SLL, prolymphocytic
leukemia (PLL), or Richter syndrome (RS) who underwent a ﬁrst unrelated
and unmanipulated allogeneic UCBT after RIC. Sixty-eight patients meeting
the study criteria were registered with the Eurocord/European Society for
Blood andMarrow Transplantation (EBMT) databases from 2004 to 2012. All
patients or legal guardians provided informed consent for the UCBT, ac-
cording to the Declaration of Helsinki.
The primary endpoint was PFS, deﬁned as the time from UCBT to relapse,
disease progression, or death. Secondary endpoints were probability of
overall survival (OS), deﬁned as the probability of survival regardless of
disease state at any point in time; incidence of neutrophil recovery, deﬁned as
ﬁrst of 3 consecutive dayswith a neutrophil count of at least .5109/L; acute
graft-versus-host disease (GVHD) at day 100 and chronic GVHD, which were
diagnosed and graded according to published criteria [17,18]; relapse ordeﬁned as deaths without previous relapse or progression. Full donor
chimerismwas deﬁned as the presence of more than 95% of the cells of donor
origin, mixed chimerism as more than 5% but less than 95% donor cells, and
autologous recovery as less than 5% of donor cells. Data on the method of
chimerism detection were not collected.
Statistical Analysis
Median values and ranges are reported for continuous variables and
percentages for categorical variables. The probabilities of OS and PFS were
calculated using the Kaplan-Meier method and the log-rank test for uni-
variate comparisons [19]. The cumulative incidence (CI) function using
death as a competing event was used to estimate neutrophil and platelet
engraftment, acute and chronic GVHD, and relapse.
The following variables were tested in the univariate analyses: age at
UCBT, year of UCBT, gender, patient cytomegalovirus (CMV) serology before
transplantation, hematopoietic stem cell transplantation comorbidity index
(HCT-CI), Binet staging at diagnosis, intervals between diagnosis and UCBT,
graft source (single/double), CLL/SLL cytogenetic risk, disease status at
transplantation (complete remission versus no complete remission), con-
ditioning regimen (low-dose total body irradiation [TBI] versus others),
antithymocyte globulin (ATG), GVHD prophylaxis (cyclosporine and myco-
phenolate mofetil versus others), number of courses of chemotherapy lines
(CTL) before UCBT, previous autologous stem cell transplantation (ASCT),
total nucleated cells per kilogram of recipient’s weight, and number of HLA
disparities. Multivariate analysis was performed using Cox proportional
hazards regression model for PFS [20]. Variables that reached a P value of .15
in the univariate analysis were included in the initial multivariatemodel and
eliminated 1 at a time in a stepwise fashion to only keep variables that
reached a P value of .05 in the ﬁnal model. P values were 2 sided. Statistical
analyses were performed with SPSS version 19 (Inc., Chicago, IL) and Splus
(MathSoft, Inc., Seattle, WA).
RESULTS
Patients and Disease Characteristics
Patients and transplantation characteristics are summa-
rized in Table 1. Sixteen patients received single and 52
received double UCBT. Seventeen patients had del 17p/
p53mutation, 19 patients had ﬂudarabine-refractory dis-
ease, 11 relapsed after ASCT, 8 had diagnosis of PLL, and 4
had RS. Median age at UCBT was 57 years (range, 26 to 68),
median year of UCBT was 2009, and median follow-up was
36 months (range, 3 to 98). Comorbidities were assessed
according to the HCT-CI [21] and scoring was as follows: 40
patients had no comorbidity, 9 had score of 1, 7 had a score
of 2, 9 had a score of 3, and 1 had a score of 4. Information
on ﬂudarabine exposure were retrieved from 67 of 68 pa-
tients. Fludarabine-refractory disease was classiﬁed as dis-
ease that failed to respond to ﬂudarabine-based treatment
or that progressed within 12 months after ﬂudarabine-
based combination regimen. Fifty-three patients were
treated with ﬂudarabine combination regimens. The other
14 patients were treated with alemtuzumab-based regi-
mens as ﬁrst-line treatment and were not considered
ﬂudarabine resistant.
Transplantation Outcomes
Neutrophil and platelet engraftment
The CI of neutrophil and platelet engraftment were 84% 
5% and 72%  6%, with a median time for engraftment of 22
(range, 5 to 67) and 44 days (range, 6 to 189), respectively.
Patients who received previous ASCT had a higher incidence
Table 1
Patients and Transplantation Characteristics
Characteristic Value (N ¼ 68)
Age, median (range) yrs 57 (27-68)
Diagnosis
CLL/SLL 56 (82%)
PLL 8 (12%)
RS 4 (6%)
Sex
Male 50 (74%)
Female 18 (26%)
Year of UCBT, median (range) 2009 (2004-2012)
Time from diagnosis to UCBT,
median (range), mo
58 (3-360)
Binet staging at diagnosis (n ¼ 54)
Stage A 18
Stage B 28
Stage C 09
Cytogenetics
Normal 13
Abnormal 35
Del 17p/p53 mutation 17
Del 13q 8
Del 11q 4
Trisomy 12 2
Complex 2
Others 2
Failed/not done 20
Previous ASCT
No 57 (84%)
Yes 11 (16%)
Single UCBT 16 (18%)
Double UCBT 52 (82%)
Conditioning regimen
Cy-Flu-TBI (2-4 Gy) 57 (84%)
Flu-TBI (2-4 Gy) 3 (4%)
Cy-Flu 2 (3%)
Cy-Flu-Thio 1 (2%)
Cy-Bu-Flu 2 (3%)
Bu-Flu-Thio 3 (4%)
GVHD prophylaxis
CsAþMMF 61 (89%)
CsAþprednisone 5 (7%)
CsAþMMFþMTX 1 (2%)
TacroþMMF 1 (2%)
ATG
No 53 (78%)
Yes 15 (22%)
HLA compatibility (n ¼ 64)
0-1 HLA MM 19 (30%)
2 HLA MM 45 (70%)
Fludarabine refractoriness (n ¼ 67)
Fludarabine-refractory disease 19 (28%)
Fludarabine-sensitive disease 48 (72%)
HCT-CI (n ¼ 66) 0-2 (56)
>2 (10)
TNC collected, median,  108 TNC/kg
(n ¼ 64)
sUCBT 3.70
dUCBT 5.04
No. of previous CTL (n ¼ 65)
1-2 23 (35%)
3 42 (65%)
Disease status at transplantation
First CR 17 (25%)
Second CR 4 (6%)
Third or higher CR 2 (3%)
Partial remission 37 (54%)
Refractory/resistant 8 (12%)
Cy indicates cyclophosphamide; Flu, ﬂudarabine; Thio, thiotepa; Bu,
busulfan; CsA, cyclosporine; MMF, mycophenolate mofetil; MTX, metho-
trexate; Tacro, tacrolimus; MM, mismatch; TNC, total nucleated cells;
sUCBT, single umbilical cord blood transplantation; dUCBT, double umbilical
cord blood transplantation; CR, complete remission.
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patients did not engraft. Of these patients, 8 died (5 died ofearly NRM without marrow reconstitution and 3 of relapse
after autologous reconstitution). Three patients are alive
with autologous reconstitution (2 of them relapsed and are
on rescue treatment and 1 is alive 13 months after trans-
plantation without signs or symptoms of relapse). For the
remaining 57 patients with neutrophil engraftment, 36 had
complete donor chimerism, 16 had mixed chimerism, and 5
were unknown.
GVHD
The CI of acute GVHD at 100 days was 42%  5% for grade
II to IV and 19%  5% for grades III and IV with a median time
of onset of 26 days (range, 9 to 95). The use of ATG was
associated with a lower risk of grade II to IV acute GVHD (14%
versus 45%, P ¼ .02). Three-year CI of chronic GVHD was 32%
 6% with a median time of onset of 138 days (range, 90 to
393). Positive CMV serology before UCBT (50% versus 22%,
P ¼ .05) was associated with higher chronic GVHD incidence
(Table 2).
NRM
Twenty-ﬁve patients died of transplantation-related
causes (10 infections, 4 post-transplantation lymphoproli-
ferative disease, 3 acute GVHD, 3 toxicity, 1 secondary lung
cancer, and 4 other causes). The cumulative incidence of
NRM was 39%  6% at 3 years. Factors associated with lower
NRM were use of low-dose TBI (2 to 4 Gy) conditioning
regimen (34% versus 62%, P < .001),  2 different CTL before
UCBT (18% versus 49%, P ¼ .02), and ﬂudarabine-sensitive
disease at UCBT (30% versus 61%, P ¼ .009) (Figure 1).
Relapse or progression
The cumulative incidence of relapse or progression was
16%  5% at 3 years. Median time to relapse or progression
was 19 months (range, 2 to 89 months) and ﬂudarabine-
sensitive disease (13% versus 45%, P ¼ .04) was the only
factor associated with lower incidence of relapse. No relapse
outcome differences were observed from del 17p and non-
17p patients (Figure 2). We analyzed the impact of acute
(P ¼ .66) and chronic GVHD (P ¼ .67) on relapse (in a time-
dependent fashion), but we could not ﬁnd any statistical
impact, probably because of low relapse rate.
Twenty-three patients underwent transplantation in
complete remission. Of these patients 15 were alive at last
follow-up and 8 died (1 of relapse after 36 months of
transplantation and 7 died of NRM causes, mainly infection).
Of the 15 patients alive, 3 relapsed with a median time to
relapse of 11 months. Thirty-seven patients were in partial
remission, 18 patients died (4 of relapse with a median time
to relapse of 19 months, 14 of NRM causes with a median
survival of 3 months), and 19 patients are alive (16 without
relapse with a median follow-up of 45months and 3 patients
relapsed with a median time to relapse of 77 months). Eight
patients had relapse-progressive disease before UCBT; 6 of
them died (2 of relapse with a median time to relapse of 7
months and 4 died of NRM with a median time to death of 2
months) and 2 are alive without relapse with a median
follow-up of 26 months.
Overall, 13 patients relapsed or progressed after UCBT.
Eight of these 13 patients underwent transplantation in
partial remission or had refractory disease at transplantation.
Of these 13 patients, 6 are alive (1 received treatment with
R-bendamustine, 1 received an unknown treatment, and 4 of
them did not receive further treatment after relapse), and 7
died (2 after relapse following a second stem cell
Table 2
Outcomes in Univariate Analysis
Variable % P Value
Neutrophil engraftment at 60 d
sUCBT versus dUCBT 84% versus 86% .71
TNC  4.7 versus > 4.7 84% versus 78% .55
HLA MM  2 versus < 2 82% versus 86% .17
Low-dose TBI versus no TBI 84% versus 83% .11
Previous ASCT versus no ASCT 100% versus 82% .03
Grade II-IV acute GVHD at 100 d
HLA MM  2 versus < 2 47% versus 35% .47
sUCBT versus dUCBT 44% versus 38% .43
TNC  4.7 versus > 4.7 34% versus 48% .22
CR versus not in CR 24% versus 49% .08
Use of ATG versus no ATG 14% versus 45% .02
Chronic GVHD at 3 yr
HLA MM  2 versus < 2 24% versus 37% .74
CR versus not in CR 37% versus 33% .68
sUCBT versus dUCBT 41% versus 32% .45
Use of ATG versus no ATG 24% versus 41% .30
TNC  4.7 versus > 4.7 37% versus 27% .24
CMV-positive versus CMV-negative serostatus 50% versus 22% .05
NRM at 3 yr
TNC  4.7 versus > 4.7 34% versus 49% .19
sUCBT versus dUCBT 46% versus 38% .21
HCT-CI  2 versus > 2 36% versus 57% .07
Age  57 yr versus > 57 yr 26% versus 52% .07
CMV-positive versus CMV-negative serostatus 46% versus 27% .09
No. CTL before UCBT  2 versus > 2 18% versus 49% .02
Fludarabine-sensitive versus
ﬂudarabine-refractory disease
30% versus 61% .009
Low-dose TBI versus no TBI 34% versus 62% <.001
Relapse incidence at 3 yr
sUCBT versus dUCBT 9% versus 14% .24
CMV-positive versus CMV-negative serostatus 14% versus 13% .51
CR versus not in CR 17% versus 11% .23
Use of ATG versus no ATG 24% versus 10% .18
TNC  4.7 versus > 4.7 14% versus 13% .40
HLA MM  2 versus < 2 9% versus 16% .90
No. CTL before UCBT  2 versus > 2 15% versus 30% .70
Fludarabine-sensitive versus ﬂudarabine-refractory disease 13% versus 45% .04
OS at 3 yr
Age  57 yr versus > 57 yr 64% versus 42% .07
sUCBT versus dUCBT 43% versus 55% .22
HLA MM  2 versus < 2 58% versus 42% .13
HCT-CI  2 versus > 2 58% versus 36% .07
CMV-positive versus CMV-negative serostatus 45% versus 70% .03
No. CTL before UCBT  2 versus > 2 59% versus 18% .01
Low-dose TBI versus no TBI 58% versus 35% <.001
Fludarabine-sensitive versus ﬂudarabine-refractory disease 70% versus 21% <.001
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patients did not receive any further treatment).
OS and PFS
The probability of OS and PFS were 54% 6% and 45% 7%
at 3 years.Negative CMVserology (70%versus45%,P¼ .03), use
of low-dose TBI (58% versus 35%, P < .001),  2 different CTL
before UCBT (59% versus 18%, P ¼ .01), and ﬂudarabine-
sensitive disease at UCBT (70% versus 21%, P < .001) were
associatedwith increasedOS (Table 2). The use of low-dose TBI
(49% versus 14%, P ¼ .02),  2 different CTL before UCBT (66%
versus 37%, P¼ .04),ﬂudarabine-sensitivedisease atUCBT (53%
versus 21%, P¼ .001), and HCT-CI 2 (51% versus 25%, P¼ .04)
were associated with improved PFS (Figure 3). Patients with
ﬂudarabine-resistant disease at UCBT frequently had  3
different CTL and advanced stage disease before UCBT. Thus,
these 3 variables were intrinsically linked in this study. The
collinearity was assessed through Fisher’s exact test that
demonstrated the association between ﬂudarabine sensitivity
with number of prior lines of chemotherapy (P ¼ .019) and
disease status at transplantation (P ¼ .044).Overall, 38 patients died or relapsed. In a multivariate
model for PFS, the use of low-dose TBI (hazard ratio [HR],
4.16 [95% conﬁdence interval, 1.33 to 12.5]; P ¼ .014), HCT-CI
score  2 (HR, 2.29 [95% conﬁdence interval, 1.0 to 5.2]; P ¼
.05), and ﬂudarabine-sensitive disease at UCBT (HR, 3.07
[95% conﬁdence interval, 1.51 to 6.25]; P ¼ .002) were asso-
ciated with improved PFS (Table 3).
Concerning the 4 patients diagnosed with RS, 3 patients
died (2 of NRM causes and 1 of relapse 8 months after
transplantation; rescue with chlorambucil was initiated,
but eventually disease progressed and the patient died 18
months after UCBT). Only 1 patient is alive after 27 months
of follow-up, without evidence of disease and with full
donor chimerism. Of the 8 PLL patients, 4 are alive
(3 without relapse and with full donor chimerism, with a
median follow-up of 13 months after transplantation; 1
patient had autologous reconstitution and relapsed 1 year
after transplantation; no further treatment was offered).
Four patients died (3 of NRM and 1 relapsed within 16
months of a second stem cell transplantation), with a
median time to death of 3.8 months after UCBT.
Figure 1. (A) NRM according to ﬂudarabine sensitivity (straight line represents ﬂudarabine-refractory CLL/SLL and dotted line represents ﬂudarabine-sensitive CLL/
SLL). (B) NRM according to the number of previous lines of chemotherapy (straight line represents patients who received 3 lines of chemotherapy and dotted
represents 2 lines of chemotherapy before UCBT).
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This study aimed to analyze the impact of UCBT in CLL/SLL
patients. Since the validation of double UCBT in 2005 by the
Minnesota group, UCBT has been extended as an alternative
stem cells source to different malignant and nonmalignant
disorders in patients lacking suitable HLA donors [16,22-24].
Approximately 15% to 20% of patients lack HLA-identical
siblings or HLA-compatible unrelated donors [25], and only
a handful of cases evaluating alternative stem cell trans-
plantation in CLL/SLL have been published so far. Bashey et al.
reported 7 CLL/SLL patients who underwent haploidentical
transplantationwith 2-year OS ranging from 44% to 55% [26].
Dodero et al. also reported 5 cases of CLL/SLL receiving
T celledepleted haploidentical transplantation [27]. Rodri-
gues et al. reported 14 CLL/SLL patients who underwent
transplantation using UCBT with encouraging results, even
for patients not in complete remission [28].More recently, the
Eurocord-EBMT group reported comparable outcomes of
UCBT and matched unrelated donors for mature lymphoid
malignancies, including 22 CLL/SLL patients [29], and theFigure 2. PFS according to del 17p/p53mutations status.Chinese group reported outcomes of a large group of patients
whounderwenthaploidentical Tcellereplete transplantation
[30]. Despite the increasing number of publications over the
last years, stem cell transplantation using alternative donors
such as UCBT in CLL/SLL is scarce in the literature.
This is the ﬁrst study to date to directly evaluate outcomes
and risk factors of UCBT for CLL/SLL. As expected in our study,
most patients underwent transplantation with double UCBT,
which historically, in adults, has been associated with higher
PFS compared with single UCBT. However, recent data have
suggested similar outcomes if a reasonable number of
nucleated cells (>2.5  108 total nucleated cells/kg) would
have been used in single UCBT [31,32]. In our study, the
majority of recipients received an adequate cell dose (>2.5)
and we could not ﬁnd outcome differences, mainly because
of the low number of patients receiving single UCBT.
Because of the small sample size, univariate analysis was
used to identify risk factors associated with engraftment,
GVHD, NRM, relapse, and OS. Although we expected lower
engraftment rates in patients with advanced disease and,
consequently, extensive marrow inﬁltration, rates of
engraftment did not changed based on disease status or
conditioning regimen, and engraftment rate in CLL/SLL was
as previously reported for other hematological malignancies
[16,33,34]. Of the 11 patients who did not engraft, only 2
patients had available HLA antibodies analysis, which were
both negative. Since the ﬁrst publication of the impact of
donor-speciﬁc antibodies in UCBT in 2010, other publications
have addressed the role of donor-speciﬁc antibodies in UCBT
[35-37]. Most transplantation centers are performing anti-
HLA antibodies before selecting the cord blood units, but
this became common, especially after 2010, and in our series
most patients received UCBT before 2010 (48 patients).
Unfortunately, we did not have data on the presence of anti-
HLA antibodies to be able to understand the incidence of
graft failure in this series.
The use of low-dose TBI did not inﬂuence engraftment.
Improved engraftment was observed in patients who had
undergone previous ASCT, probably because of higher degree
of immune suppression before allogeneic transplantation.
This observation has been previously reported in UCBT [38].
Most ASCT were performed before 2009, when data on
prospective studies analyzing the impact of ASCT in OS were
not yet available.
Regarding acute and chronic GVHD, the incidences were
quite high when compared with other hematological
Figure 3. (A) Overall PFS from the entire cohort of patients. (B) PFS according to ﬂudarabine sensitivity.
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infrequent use of ATG, common use of double UCBT, and
high-risk disease status at transplantation [40-42].
Used as an alternative stem cell source, umbilical cord
blood has been indicated in patients usually in a very
advanced/refractory stage of disease. In our study, approxi-
mately two thirds of our patients underwent transplantation
for poor-risk disease (del 17p/p53mutation, ﬂudarabine-
refractory disease, or diagnosis of PLL or RS), and higher
tumor burden before RIC-UCBT has been associated with
worst outcomes [43]. Importantly, the median age of our
patients was 57 years, most of patients received 3 or more
chemotherapy regimens before transplantation, and 15% of
patients had an HCT-CI  3, reﬂecting this poor-risk popula-
tion and the burden of comorbidities, which could, in part,
explain the NRM reported. Higher comorbidity scores and
type of conditioning regimen have long been associated with
increased NRMand reduced PFS in CLL [14,44]. Myeloablative
conditioning has been associated with increased NRM when
compared with RIC transplantations [14,45]. Despite
analyzingonly patients undergoingRIC, anunexpectedlyhigh
rate of NRMwas observed (39%). This could be also because of
delayed engraftment and immune reconstitution and a
higher risk of infection associated with UCBT [43,46,47-49].
We found 3 factors associated with improved PFS in
multivariate analysis: use of low-dose TBI, lower HCT-CI
scores, and ﬂudarabine-sensitive disease at UCBT. Patients
who received low-dose TBI had better PFS compared with
patients who did not receive radiation, which was previously
noticed by an analysis of the EBMT group [28]. Although,
there has never been a prospective randomized comparison
between TBI versus non-TBI regimens in the RIC setting,
excellent long-term outcomes have been reported in patients
who underwent a reduced-intensity TBI-based regimen in
matched related donor or matched unrelated donor trans-
plantation [12,50]. Low-dose TBI and low HCT-CI scores wereTable 3
Univariate and Multivariate Analysis for PFS at Three Years
Variable Univaria
HCT-CI  2 versus > 2 51% ver
Low-dose TBI versus no TBI 49% ver
Fludarabine-sensitive disease versus ﬂudarabine-refractory disease 57% ver
Age  57 yr versus > 57 yr 54% verassociated with superior PFS because of lower NRM; these
variables did not inﬂuence relapse. On the other hand,
ﬂudarabine-sensitive disease was associated with lower
NRM and lower relapse incidence.
Purine analogueeresistant disease had poor PFS (re-
fractory CLL/SLL had a 3-year PFS of 21%) mainly because of
the higher number of CTL and more advanced disease at
UCBT, which could explain the higher associated NRM in this
group of patients. Moreover, bacterial infections were the
main cause of NRM and strategies to prevent it should be
investigated in future studies on RIC-UCBT in CLL/SLL.
Improvement in supportive therapy and infectious prophy-
laxis are currently ongoing for those patients who are highly
immunosuppressed [51]. Because of delayed engraftment
and higher risk of graft failure in UCBT, strategies to improve
engraftment are in the spotlight of many clinical trials.
Ex vivo expansion of the cord blood unit is becoming an
interesting ﬁeld of research in different countries, mainly in
the United States. Different techniques of ex vivo expansion
(Notch, CXCR4 cell pathway, or cytokines stimulations) are
under research, but no preferable technique has come forth
as the standard [52,53]. With earlier engraftment and higher
engraftment rates, the incidences of bacterial and fungal
infections are decreased.
Fludarabine-refractory disease was also associated with
higher incidence of relapse. As NRM is a competitive risk for
disease relapse and knowing that NRM was high in patients
with ﬂudarabine-refractory disease, the actual relapse rate in
this group of patients is, indeed, underestimated (it is
possible that patients with ﬂudarabine-refractory disease
who died of early NRMmay have experienced relapse if they
remained alive). Despite the poor-risk patient population in
this study, relapse incidence was relatively low, which could
be because of the GVL effect that can be active, even in high-
risk cytogenetic categories. Analyzing only patients with
available cytogenetics, no relapse outcome differences werete Analysis Multivariate Analysis
sus 25%, P ¼ .04 HR, .45 (95% conﬁdence interval, .20-1.00); P ¼ .05
sus 14%, P ¼ .02 HR, .25 (95% conﬁdence interval, .08-.78); P ¼ .017
sus 21%, P ¼ .001 HR, .32 (95% conﬁdence interval, .16-.66); P ¼ .002
sus 34%, P ¼ .17 HR, .68 (95% conﬁdence interval, .35-1.33); P ¼ .26
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tion has been previously reported, thus reinforcing the GVL
effect, even in high-risk cytogenetic patients [54]. The role of
minimal residual disease (MRD) before transplantation in
the setting of allo-HSCT for CLL has yet to be clearly deﬁned.
Because of different monitoring techniques and thresholds,
multicenter studies are difﬁcult, and no cut-off values have
been accepted worldwide [55]. Few studies have addressed
the role of MRD before transplantation in CLL, and these
studies are limited with small sample cohorts [56]. Instead of
MRD, a post-transplantation tool associated with relapse is
chimerism status, which can inﬂuence post-transplantation
MRD as rapid T cell engraftment is associated with lower
MRD and relapse rate [57]. In our study, the CI of relapse in
patients who achieved full donor chimerism before day 100
after UCBT was only 5%, whereas in patients with mixed
chimerism before day 100, the incidence of relapse was 36%.
The immunologic reaction of the graft against the leukemic
cells has been reported to decrease incidence of relapse
[58-61]. Even with the impossibility of donor lymphocyte
infusion after UCBT, several studies reported a strong GVL
effect using UCBT without an increased incidence of chronic
GVHD [62,63]. Another risk factor that has an impact in the
relapse rate in CLL is the presence of bulky disease before
transplantation [58,64]. Unfortunately, the characteristic of
size masses was not reported by the participating centers;
therefore, we could not assess the impact of bulky disease in
this study.
Different strategies to overcome the poor prognosis of
refractory CLL have been tried and with the advent of new
therapeutic options (Bcl-2 antagonists, Bruton’s kinase in-
hibitors, new monoclonal antibodies) that are effective and
with lower toxicity, even in chemo-resistant CLL/SLL, selec-
tion of patients for allo-HSCT is becoming more difﬁcult
because of high NRM, even in RIC setting [2,11,65,66]. How-
ever, longer follow-up is needed to evaluate long-term out-
comes of these drugs and resistance to Bruton’s kinase
inhibitors has already been reported [67]. Still, better long-
term disease control after allo-HSCT may lead to better
overall results long term. Although no potential cure has
been described with novel therapy tools, pretransplantation
cytoreduction could have an impact on post-transplantation
outcomes and maintenance strategies after transplantation
could be of a great value in reducing relapse rate, at least
until the GVL effect exerts its immunologic reaction on
leukemic cells.
One could argue that our series of patients is biased as
many studies have described a higher frequency of
ﬂudarabine-refractory disease before HSCT (this is 1 of the
main indications for allogeneic stem cell transplantation in
CLL) [8]. In fact, in our series, only 19 patients had
ﬂudarabine-refractory disease, but of the 48 patients without
ﬂudarabine-resistant disease, 3 had diagnosis of Richter
transformation, 8 had PLL, 12 had del 17 p, and 3 had del 11 q,
which are high-risk features of disease.
Although there are intrinsic limitations of interpreting
the results of a small sampleesized study, this retrospective
multicenter analysis shows favorable PFS in this poor-risk
CLL/SLL population. Overall, outcomes after UCBT seem to
approach those of identical HLA-matched transplantation
[14,15,64,68]. Despite the small number of patients, the good
results support the use of low-dose TBI (mainly cyclophos-
phamide, ﬂudarabine, and TBI) as a RIC regimen in UCBT. This
approach has previously been associated with good out-
comes [69,70]. In conclusion, RIC-UCBT using low-dose TBIappears to be a valid option of allo-HSCT for CLL/SLL patients
lacking an HLA-matched donor. Strategies to enhance
engraftment, optimization of infection prophylaxis, and trials
comparing different conditioning approaches are need to
improve future outcomes.ACKNOWLEDGMENTS
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